SAN DIEGO, CA--(Marketwire - Mar 7, 2013) - BioLegend in San Diego, CA, a leading provider of antibodies and reagents for biomedical research, has been granted ISO 9001:2008 certification for ...
NEW YORK--(BUSINESS WIRE)--BioLegend, Inc. (“BioLegend”) and the New York Genome Center (“NYGC”) announced today that they have entered into an exclusive worldwide license and collaborative research ...
BioLegend can breathe a bit easier. The San Diego biological research products supplier, which had been cramped for space, opened a new and larger headquarters this week. BioLegend has more than 500 ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE - In this Feb. 11, 2021, file photo is the exterior of the PerkinElmer lab in Valencia, Calif. PerkinElmer will spend about ...
PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
San Diego-based Biotech firm BioLegend Inc. has begun work on a new campus in Miramar, with an expected project cost of more than $100 million. A company spokeswoman said a ground-breaking was held ...
(Reuters) - Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash ...
PerkinElmer Inc. said it is buying BioLegend, which provides life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. PerkinElmer said Monday the transaction is ...
BioLegend can breathe a bit easier. The San Diego biological research products supplier, which had been cramped for space, opened a new and larger headquarters this week. BioLegend has more than 500 ...
PerkinElmer, Inc. PKI recently completed its buyout of BioLegend for a total consideration of approximately $5.25 billion. The latest buyout, which is historically the largest for the company, is ...
Medical diagnostic firm PerkinElmer Inc said on Monday it would buy BioLegend, a privately held maker of reagents and antibodies used in medical research, for about $5.25 billion in a cash-and-stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results